Krstevska balkanov, Svetlana
Preferred name
Krstevska balkanov, Svetlana
Official Name
Krstevska balkanov, Svetlana
83 results
Now showing 1 - 10 of 83
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Прогностичко одредување на исходот од лекување со автологна трансплантација на матични хематопоетски клетки(SHMSHM - AAMD, 2012); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, IMPACT OF INITIAL RENAL INVOLVEMENT AND BENCE JONES PROTEINS IN THE URINE ON OVERALL SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA(Macedonian Association of Anatomists, 2022); ; ; ; Ridova, Nevenka - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Chronic Graft-Versus Host Disease - Single Center Experience(Scientific Foundation SPIROSKI, 2008-09-01); ; ; ; Gocev, Georgi - Some of the metrics are blocked by yourconsent settings
Item type:Publication, CML-053 Health-Related Quality of Life in Macedonian Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: EQ-5D-5L Assessment(Elsevier BV, 2024-09); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Iron overload in patients with transfusion dependent myelodysplastic syndrome(Македонска академија на науките и уметностите, Одделение за биолошки и медицински науки = Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences, 2011-07); ; ; ; The myelodisplastic syndrome is a heterogeneous group of diseases, characterised by ineffective and dysplastic haematopoesis and pancytopenia in the peripheral blood, followed by progressive disturbance of differentiation of the haematopoetic stem cell, resulting in evolution of the disease towards acute leukaemia. According to the latest WHO classification, the term myelodisplastic syndrome includes diseases with an indolent course, as well as diseases with a fast evolution towards acute leukaemia. Because of this diversity, haematologists base their therapeutic decisions on prognostic scoring systems which incorporate all the significant factors with an influence on survival in this group of patients with myelodisplastic syndrome. Bearing in mind that anaemia is the most frequent form of cytopenia in patients with myelodisplastic syndrome, it is common that at some point of the disease almost every patient with myelodisplastic syndrome is transfusion-dependent. Frequently applied transfusions secure the correction of anaemia in these patients, giving them a good quality of life, but at the same time endangering them with the potential threat of iron overload, when the physiological mechanisms of iron excretion from the organism become insufficient. There is a clear correlation between transfusion dependence and the overall survival in patients with myelodisplastic syndrome. Chelators secure the lowering of the iron surfeit and are indicated in transfusion-dependant patients with myelodisplastic syndrome ( need for two blood units monthly, during one year ), when the ferritin level increases over 1000, in patients who are candidates for transplantation as well as in patients from good prognostic groups with median survival over one year. The therapy with chelators lasts as long as the patient is transfusion-dependant. Key words: myelodisplastic syndrome, chelators, iron overload - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The evaluation of some markers of proximal renal tubules damage in patient with psoriatic arthritis(Macedonian Medical Association, 2018); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hematologic Autoimmune Manifestation Secondary to Coronavirus Disease 19 Infection – A Single-Center Experience(Scientific Foundation SPIROSKI, 2021-09-11); ; ; <jats:p>Introduction: Since December 2019, multiple human cases of novel coronavirus infection were reported, representing with upper respiratory symptoms (influenza-like presentation). The virus was named the Severe acute respiratory system coronavirus 2 (SARS-COV-2). Studies have reported cases of patients with COVID-19 infection, including development of several autoimmune events that suggests that infection with SARS CoV-2 may be associated with initiation of autoimmune hematological autoimmune disorders. Aim: Review the hematological autoimmune phenomenon after infection with SARS-COV-2 in order to assist into the pathogenic mechanisms, clinical manifestations and treatment of this group of patients. Materials and methods: This is a retrospective study that includes 21 patients with autoimmune diseases like secondary immune thrombocytopenia (ITP), autoimmune hemolytic anemia( AIHA) and thrombotic thrombocytopenic purpura (TTP) that have emerged after COVID-19 infection. The patients were diagnosed and treated at the University Clinic of Hematology for a period of time from January 2020 to April 2021. Results: The most common hematologic autoimmune disorder was ITP in 13 cases (62%) followed by AIHA in 5 cases (24%) and TTP in 3 individuals (14%). The mean time of onset of the hematologic auto-immune presentations was 18,4 ± 10,3 days. The therapy of this conditions in patients with COVID-19 infection requires an individualized approach to achieve a precise balance between the risk of severe bleeding and of thromboembolic events. Conclusion: Causal relationship between COVID-19 infection and these autoimmune events still requires further studies. We should all have in mind the risk of development of hematologic autoimmune disorders in infected patients. </jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, P095 Long term follow up of autologous transplant in AML patients in first complete remission(Elsevier BV, 2007-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Autologous Hematopoetic Stem Cell Transplantation as An Intensive Consolidation Therapy for Adult Patients in Remission from Acute Myeloid Leukemia(American Society of Hematology, 2010-11-19); ; ; ; <jats:title>Abstract</jats:title> <jats:p>Abstract 4595</jats:p> <jats:p>Despite advances in our understanding of its pathogenesis, acute myeloblastic leukemia remains difficult to treat. Although initial complete remission can be achieved in a high percentage of patients, relapse occurs in 70–80% of the patients. Two main approaches have been the attempt to eradicate the leukemic clonal cells population via chemotherapy with or without autologous stem cell rescue or to pursue a combined approach using an antileukemic therapy combined with an antileukemic immune response via allogeneic bone marrow transplantation. Autologous transplantation compares favorably against allogeneic bone marrow transplant in several ways. Autologous transplantation can be used as a consolidation therapy in the older population, and lack of a matched donor does not preclude the patients from this treatment.</jats:p> <jats:p>We report a retrospective analysis on 48 patients diagnosed with de novo AML, who did not have an available histocompatible donor, and who underwent autologous transplantation between years 2000–2009 at the University hematology Clinic, Skopje, Macedonia. All patients had ECOG score 1 or less. The patient's age ranged from 17 to 65 years with the median age 41 years. There were 26 males and 22 females. For stem cell mobilization patients received chemotherapy or chemotherapy plus G-CSF. The preparative chemotherapy regimen prior to autologous transplantation consisted of BuCy in 24 patient, BEAM in 22 and BuCyMel was used in the remaining 2 patients. We used bone marrow as primary source of stem cells in 18 patients, and peripheral blood stem cells in remaining 30 patients.</jats:p> <jats:p>The five years overall survival was 52% and the 5 years disease progression free survival were 42%. We analyzed sever factors that can influence the overall survival and the disease free survival such as: age, disease status, stem cell source, chemotherapy regiments prior to transplantation, conditioning regiments, number of mobilized stem cells. Advanced age and bone marrow stem cell source seems to be more influent factors.</jats:p> <jats:p>We report that the clinical results of autologous hematopoietic stem cell transplantation are sufficiently encouraging to warrant future trials that include autologous transplantation as an option for appropriately selected patients with AML in CR1. We conclude that autologous hematopoietic stem cell transplantation is a reasonable and save intensive consolidation for patients with acute myeloblastic leukemia who do not have a suitable HLA–matched donor.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, INEFFECTIVE ERYTHROPOIESIS IN PATIENT WITH BETA THALASSEMIA AND MYELODYSPLASTIC SYNDROME CASE REPORT(Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2024); ; ;